Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | BAY2666605 |
Trade Name | |
Synonyms | BAY 2666605|BAY-2666605|Doxorubicin-loaded EGFR-targeting Nanocells |
Drug Descriptions |
BAY2666605 induces formation of the SLFN12-PDE3A complex, leading to stimulation of SLFN12 activity and decreased inhibition of PDE3A enzymatic activity, potentially reducing cancer cell viability and inhibiting tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 2663). |
DrugClasses | |
CAS Registry Number | 2275774-60-0 |
NCIT ID | C180380 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
BAY2666605 | BAY2666605 | 0 | 1 |